๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-08-17

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease (NCT00424866)

A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication

๐ŸŸก Not Yet Recruiting Phase1 / Phase2 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: Venturis Therapeutics, Inc.

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.

Who can join: Review the eligibility criteria below.

Location: Venturis Therapeutics โ€” Chicago, Illinois

Age range: 50 Years to 75 Years

๐Ÿงช Interventions in This Study

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (1 Sites)

  • Venturis Therapeutics โ€” Chicago, Illinois

๐Ÿ“ž Contact the Study Coordinator

Phone: (415) 306-6333

Email: LMeyerson@venturistherapeutics.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—